Edwards received notification from our affiliate in spain.As reported, this was a case of an implant of 29mm edwards sapien 3 transcatheter heart valve, in aortic position by transfemoral approach.The patient had a history of severe aortic stenosis (as) and severe calcification and tortuosity in both iliac arteries.It was decided to access through the left femoral artery and a balloon pre-dilation was performed.During the introduction of the esheath it was not able to navigate.The sheath was removed and a new sheath was inserted.The valve was implanted successfully and the patient was stable.Post procedure images of the esheath were provided and showed a distal tip split.
|
The device was not returned for evaluation.Therefore, a no product return engineering evaluation was performed.A review of imagery was performed, and the following was observed: tortuosity present in patient's access vessel.Distal tip was open and split along the hdpe proximal to the axial score line.The device history record (dhr) review did not reveal any manufacturing nonconformance issues that would have contributed to the event.A lot history review was performed and revealed no other complaints relating to this event.A review of edwards lifesciences risk management documentation was performed for this case.The reported event is an anticipated risk of the transcatheter heart valve procedure, additional assessment of the failure mode is not required at this time.The complaints of esheath distal tip split and sheath insertion inability were confirmed through evaluation of the imagery.As the device was not returned, engineering was unable to perform any visual inspection, functional testing, or dimensional analysis.Therefore, the presence of a manufacturing non-conformance was unable to be determined.However, review of the dhr, lot history, and complaint history did not provide any indication that a manufacturing non-conformance would have contributed to the complaint event.A review of ifu/training materials revealed no deficiencies.Furthermore, there was no report of any issues with the sheath during device unpacking or preparation.As reported, ''the patient had severe aortic stenosis and severe calcification and tortuosity in both iliac arteries.It was decided to access through the left femoral artery and a bav was performed.Then, during the insertion of the esheath it was not possible to navigate.The esheath was removed, replaced with a new esheath which could be correctly inserted''.The patient was noted to have ''severe calcification and tortuosity''.Tortuous patient anatomy can also be observed in the returned patient imagery.The procedural training manual states, ''push force can vary due to angle of insertion, vessel diameter, tortuosity and degree of calcification''.It is likely that vessel calcification and tortuosity created a challenging pathway for sheath insertion through added friction from interaction with calcification and sub-optimal angles from tortuosity, which may have required additional force and device manipulation to overcome.Sheath interaction with calcification coupled with excessive manipulation can cause the sheath tip to split.As such available information suggests that patient (calcification, tortuosity) and/or procedural (excessive manipulation) factors may have contributed to the reported event.No labeling/ifu deficiencies were identified.Therefore, no corrective or preventative actions, nor product risk assessment (pra) is required at this time.Complaint histories for all reported events are reviewed against trending control limits monthly, and any excursions above the control limits are assessed and documented as part of this monthly review.
|